Alvogen
As of the edition of 20 October 2026, Alvogen runs 8 drugs, 7 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Levothyroxine | none listed | 6 |
| Teriparatide | none listed | 3 |
| Labetalol | none listed | 14 |
| Flecainide | none listed | 0 |
| Fluocinonide | none listed | 1 |
| Ciclopirox | none listed | 0 |
| Econazole | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Heart and blood vessels: 1 trials led